

Winston & Strawn LLP
101 California Street
San Francisco, CA 94111-5802

James F. Hurst (*Admitted Pro Hac Vice*)
David J. Doyle (*Admitted Pro Hac Vice*)
Samuel S. Park (*Admitted Pro Hac Vice*)
Stephanie S. McCallum (*Admitted Pro Hac Vice*)
WINSTON & STRAWN LLP
35 W. Wacker Drive
Chicago, IL 60601-9703
Telephone: 312-558-5600
Facsimile: 312-558-5700
Email: jhurst@winston.com;
ddoyle@winston.com;
spark@winston.com; smccallum@winston.com

Nicole M. Norris (SBN 222785)
WINSTON & STRAWN LLP
101 California Street, Suite 3900
San Francisco, CA 94111-5894
Telephone: 415-591-1000
Facsimile: 415-591-1400
Email: nnorris@winston.com

Charles B. Klein (*Admitted Pro Hac Vice*)
Mathew A. Campbell (*Admitted Pro Hac Vice*)
WINSTON & STRAWN LLP
1700 K Street, N.W.
Washington, D.C. 20007
Telephone: 202-282-5000
Facsimile: 202-282-5100
Email: cklein@winston.com

Jeffrey I. Weinberger (SBN 56214)
David M. Rosenzweig (SBN 176272)
Grant A. Davis-Denny (SBN 229335)
MUNGER, TOLLES & OLSON LLP
355 Grand Avenue
Los Angeles, CA 90071-1560
Telephone: (213) 683-9100
Facsimile: (213) 687-3702
Email: jeffrey.weinberger@mto.com;
david.rosenzweig@mto.com;
grant.davis-denny@mto.com

Michelle Friedland (SBN 234124)
MUNGER, TOLLES & OLSON LLP
560 Mission Street, 27th Floor
San Francisco, CA 94105-2907
Telephone: (415) 512-4000
Facsimile: (415) 512-4077
Email: michelle.friedland@mto.com

Attorneys for Defendant
ABBOTT LABORATORIES

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
OAKLAND DIVISION

SMITHKLINE BEECHAM CORPORATION)
d/b/a GLAXOSMITHKLINE,)

Plaintiff,)

v.)

ABBOTT LABORATORIES,)

Defendant.)

Case No. C07-5702 (CW)
(Consolidated Cases)

Related per November 19, 2007 Order to
Case No. C04-1511 (CW)

**STIPULATION RESOLVING CERTAIN
OUTSTANDING FACT DISCOVERY
ISSUES**

1 WHEREAS, the parties completed fact discovery on February 27, 2009, with the exception
2 of certain issues for which this Court has extended the discovery deadline in Orders dated February
3 25, 2009 (Dkt. 130), March 13, 2009 (Dkt. 142), March 17, 2009 (Dkt. 147), March 20, 2009 (Dkt.
4 150), April 29, 2009 (Dkt. 159), and May 18, 2009 (Dkt. 161);

5 WHEREAS, the current deadline for motions to compel relating to written discovery served
6 in January 2009 by Abbott Laboratories ("Abbott") on GlaxoSmithKline ("GSK"), and by GSK on
7 Abbott, as set out in the May 18, 2009 order, is May 21, 2009;

8 WHEREAS, the current deadline for motions to compel relating to certain enumerated
9 potential deficiencies relating to each party's production of documents, as set forth in the May 18,
10 2009 order, is May 21, 2009;

11 WHEREAS, the parties are continuing to discuss resolution of two outstanding disputes,
12 namely Abbott's Response to GSK Interrogatory No. 17, and Abbott's request to reopen fact
13 discovery for the limited purpose of obtaining from GSK's third party vendors the supporting
14 materials underlying those vendors' marketing and pricing studies of Lexiva conducted for GSK;

15 WHEREAS, the parties have reached a resolution to their remaining disputes concerning the
16 fact discovery referenced within those Orders, and in so doing, have made certain representations to
17 each other;

18 WHEREAS, the parties wish to memorialize those representations and their resolution of
19 these outstanding discovery disputes;

20 **IT IS HEREBY STIPULATED AND AGREED:**

21 1. As soon as practicable, GSK will designate witnesses to testify on GSK's behalf
22 concerning Topic Nos. 2, 7, 12, 13 and 14 of Abbott's January 14, 2009 Notice of 30(b)(6)
23 Deposition. The parties will work together to agree on mutually convenient dates for the deposition
24 of any witness designated by GSK on these topics.

25 2. With respect to certain other topics in Abbott's January 14, 2009 Notice of 30(b)(6)
26 Deposition, Abbott agrees to accept the prior testimony of GSK witnesses in this and the related
27 cases as 30(b)(6) testimony as set forth below:

Designated 30(b)(6) Witness**Notice Topic(s)**

Michael Hannan

1, 3, 5, and 6

Mark Shaefer

8, 9, and 10

Marlon Pittman

11

Peter Hare

15

John Keller

16, 17 and 18

GSK represents that the above-designated witnesses are officers, directors or managing agents of GSK or have consented to testify on GSK's behalf on the topics for which they are designated above. GSK also agrees that any testimony provided by these witnesses on a topic for which they are designated above can be used in this or the related cases in the same manner as if GSK had properly designated the witnesses under Rule 30(b)(6) prior to their depositions.

3. Abbott agrees that it will not ask GSK to designate a witness to testify concerning topics 19, 20 or 21 from Abbott's January 14, 2009 Notice of 30(b)(6) Deposition.

4. Abbott agrees to amend further its response to Interrogatory No. 16 of GSK's Second Set of Interrogatories within two (2) weeks after completion of the deposition of a witness designated to testify on GSK's behalf on Topic No. 14 of Abbott's January 14, 2009 Notice of 30(b)(6) Deposition.

5. GSK and Abbott agree that any motion to compel by GSK relating to Abbott's response to GSK Interrogatory No. 17 shall be filed by May 28, 2009; and that any such motion should be initially filed in the form of a 2-page letter brief before Judge Zimmerman;

6. GSK and Abbott agree that any motion by Abbott to reopen fact discovery for the limited purpose of obtaining from GSK's third-party vendors the supporting materials underlying those vendors' marketing and pricing studies of Lexiva conducted for GSK shall be filed by May 28, 2009;

7. Nothing in this stipulation shall expand the parties' rights to seek relief by the Court on any discovery issue except as set forth herein.

/s/ Trevor Stockinger

/s/ Charles B. Klein

Dated: May 26, 2009

Candice Witt

Judge Claudia Wilken
United States District Court
Northern District of California